Antioxidant supplementation has a positive effect on oxidative stress and hematological toxicity during oncology treatment in cervical cancer patients
Background and aim
Hematological toxicity and oxidative stress are common in cancer patients. Antioxidant supplementation has been shown to decrease oxidative stress, but there is still controversy on this topic. The aim of this study was to determine the effect of antioxidant supplementation on oxidative stress, hematological toxicity, and quality of life (QoL) in cervical cancer patients.
Randomized, single-blinded controlled trial in women with cervical cancer treated with radiotherapy and chemotherapy with cisplatin. Subjects were randomly assigned to receive antioxidant supplement or placebo supplement. Plasma concentrations of malondialdehyde, free carbonyls, and blood biometry were measured. EORTC quality of life questionnaire was applied before and after oncology treatment. Student’s t test for independent samples and X2 for categorical variables were performed.
One hundred three patients were randomly assigned to receive treatment with antioxidants 49 (48 %) or placebo 54 (52.40 %). At the end of the oncology treatment, hemoglobin levels were maintained, and global QoL was better only in the supplemented group (p < 0.025).
Antioxidant supplementation in patients treated with chemotherapy and radiotherapy apparently decreased oxidative stress, maintained hemoglobin levels, and improved QoL; however, more studies are needed to study the long-term effect of this intervention.
KeywordsCervical cancer Oxidative stress Antioxidant therapy Hematological toxicity and quality of life (QoL)
- 1.Instituto Nacional de Estadística, Geografía e Informática (INEGI). (2009) Datos nacionales a propósito del día mundial contra el cáncer. Report from INEGI. It is available in: http://www.inegi.org.mx/inegi/contenidos/espanol/prensa/contenidos/estadisticas/2009/cancer09.asp?s=inegi&c=2680&ep=9: Consulted in December, 2011
- 2.Shapiro WR, Young DF (1984) Neurological complications of antineoplastic therapy (Abstract). Acta Neurol Scand Supp 100:125–132Google Scholar
- 4.Luján P (2004) Radioterapia en el cáncer cérvico uterino. In: Torres-Lobatón A (ed) Cáncer ginecológico: diagnóstico y tratamiento. McGraw-Hill, México, pp 43–56Google Scholar
- 5.Lira VM (2004) Quimioterapia del cáncer cérvico uterino. In: Torres-Lobatón A (ed) Cáncer ginecológico: diagnóstico y tratamiento. McGraw-Hill, México, pp 84–85Google Scholar
- 6.Sociedad Española de Oncología Médica. Toxicidad hematológica. Inform by SEOM, 2011 (Published in January 17th, 2011). It is available in: URL:http://www.seom.org
- 8.Elejalde JJ (2001) Estrés oxidativo, enfermedades y tratamientos antioxidantes. An Med Interna 18(6):326–235Google Scholar
- 9.Conklin KA (2004) Cancer chemotherapy and antioxidants. J Nutr 134(Suppl):3201–3204Google Scholar
- 18.Cecilia G, Davies KJA (1993) Dityrosine and tyrosine oxidation products are endogenous markers for the selective proteolysis of oxidatively modified red blood cell hemoglobin by (the 19 S) proteasome. J Biol Chem 268(12):8725–8759Google Scholar